How do you manage grade 2-3 chemotherapy- induced peripheral neuropathy (CIPN) developing during adjuvant paclitaxel therapy for breast cancer?
How would you manage symptoms? How would you adjust the adjuvant regimen (dose reduce, omit paclitaxel etc)? What strategies would you consider for preventing CIPN in other patients undergoing adjuvant paclitaxel?
Community PollStarted
How do you approach grade 2-3 chemotherapy- induced peripheral neuropathy (CIPN) developing during adjuvant paclitaxel therapy for breast cancer?
55 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Huntsman Cancer Institute at the University of Utah
Answered on
In cases with grade 2-3 neuropathy, I consider dose reduction of paclitaxel by at least 20%. I have also used duloxetine (30 mg daily for the 1st week and then 60 mg daily based on the randomized study by Smith et al (JAMA 2013)), with fair amount of success. I have also used gabapentin, although wi...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Wisconsin School of Medicine and Public Health
Answered on
CTCAE grading for peripheral motor sensory neuropathy remains a bit challenging, as Grade 1 is asymptomatic and grade 2 is already moderate (or limiting IADLs). However, I do agree with the 20% dose reduction if patients have moderate symptoms or impact on IADLs, and have also utilized duloxetine wi...
Join for free or sign in to see the full answer